Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 1/2000

01-01-2000

Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors

Authors: W. Hu, P.D. McCrea, M. Deavers, J.J. Kavanagh, A.P. Kudelka, C.F. Verschraegen

Published in: Clinical & Experimental Metastasis | Issue 1/2000

Login to get access
Metadata
Title
Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors
Authors
W. Hu
P.D. McCrea
M. Deavers
J.J. Kavanagh
A.P. Kudelka
C.F. Verschraegen
Publication date
01-01-2000
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 1/2000
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1023/A:1026596609969

Other articles of this Issue 1/2000

Clinical & Experimental Metastasis 1/2000 Go to the issue

OriginalPaper

Activated leukocyte cell adhesion molecule (ALCAM) and annexin II are involved in the metastatic progression of tumor cells after chemotherapy with Adriamycin

OriginalPaper

Behaviour of metastasis in relation to vascular index in patients with node-positive breast cancer treated with adjuvant tamoxifen

OriginalPaper

A highly metastatic Lewis lung carcinoma orthotopic green fluorescent protein model

OriginalPaper

Cyclooxygenase-2 expression in colorectal cancer liver metastases

OriginalPaper

The impact of laparoscopic biopsy of pancreatic lymph nodes with helium and carbon dioxide on port site and liver metastasis in BOP-induced pancreatic cancer in hamster

OriginalPaper

Interaction of tumor cells with vascular endothelia: Role of platelet-activating factor
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits